Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MXCT

MaxCyte Inc

Sep 15 • 03:25PM ET

1.45

0.00 0.00 %

Healthcare • Medical Devices • USA • NASD

Peers: NTLA CRSP EDIT SGMO BEAM CRBU CDXS ABCL ALLO

| Held by: VTI IWM VXF IWN VTWO IBB VHT IWC DFAS AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.42	Insider Own	8.45%	Shs Outstand	106.59M	Perf Week	2.84%
Market Cap	154.58M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	3.87%	Shs Float	97.60M	Perf Month	2.84%
Enterprise Value	46.53M	PEG	-	EPS next Q	-0.11	Inst Own	71.42%	Short Float	3.37%	Perf Quarter	-34.09%
Income	-44.77M	P/S	4.32	EPS this Y	-6.93%	Inst Trans	-1.48%	Short Ratio	4.16	Perf Half Y	-55.93%
Sales	35.75M	P/B	0.81	EPS next Y	4.27%	ROA	-19.00%	Short Interest	3.29M	Perf YTD	-65.14%
Book/sh	1.79	P/C	1.22	EPS next 5Y	1.15%	ROE	-21.73%	52W High	5.20 -72.12%	Perf Year	-62.92%
Cash/sh	1.19	P/FCF	-	EPS past 3/5Y	-22.97% -11.37%	ROIC	-21.53%	52W Low	1.26 15.08%	Perf 3Y	-77.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.45% 12.31%	Gross Margin	68.10%	Volatility	5.08% 5.17%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.30	EPS Y/Y TTM	-24.21%	Oper. Margin	-146.80%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.71	Sales Y/Y TTM	-21.32%	Profit Margin	-125.22%	RSI (14)	43.26	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	12.39	EPS Q/Q	-29.58%	SMA20	3.17%	Beta	-	Target Price	6.68
Payout	-	Debt/Eq	0.10	Sales Q/Q	-18.43%	SMA50	-17.05%	Rel Volume	0.26	Prev Close	1.45
Employees	114	LT Debt/Eq	0.09	Earnings	Aug 06 AMC	SMA200	-50.01%	Avg Volume	790.81K	Price	1.45
IPO	Dec 05, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-20.00% -11.21%	Trades		Volume	191,062	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-25	Downgrade	BTIG Research	Buy → Neutral
Aug-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-25	Initiated	Stephens	Overweight	$6
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Show Previous Ratings

Aug-11-25 07:45AM	MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio (Insider Monkey)
Aug-06-25 06:10PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -29.90%
04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 10:27AM	MaxCyte Inc (MXCT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
08:05AM	Loading…
Jul-31-25 08:05AM	MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline (GlobeNewswire)
Jul-09-25 08:05AM	MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 01:00AM	PHC Announces Exclusive Distribution of MaxCyte® ExPERT Platform in Japan (Business Wire)
Jun-11-25 02:00AM	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies (GlobeNewswire)
May-13-25 10:51AM	MaxCyte, Inc. (MXCT): A Bull Case Theory (Insider Monkey)
May-08-25 03:27AM	MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ... (GuruFocus.com) -11.31%
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance (GlobeNewswire)
Apr-10-25 02:00AM	MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire) -7.51%
Apr-08-25 09:35AM	Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) (Zacks) -5.67%
09:35AM	Loading…
Apr-07-25 09:35AM	Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround (Zacks)
Apr-04-25 12:00PM	MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know (Zacks) -5.77%
Mar-12-25 03:07AM	MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges (GuruFocus.com) -8.36%
Mar-11-25 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance (GlobeNewswire)
Feb-12-25 02:00AM	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs (GlobeNewswire)
Feb-07-25 02:00AM	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-30-25 02:00AM	MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments (GlobeNewswire)
Jan-15-25 12:00PM	All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy (Zacks)
Jan-13-25 03:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) +11.59%
Dec-23-24 02:00AM	MaxCyte Announces Retirement of Board Member Art Mandell (GlobeNewswire)
Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
08:05AM	Loading…
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire) -10.44%
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)
May-14-23 03:11AM	Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive (Simply Wall St.)
May-10-23 05:25PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -19.78%
04:05PM	MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
May-04-23 08:05AM	MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform (GlobeNewswire)
Apr-28-23 05:03AM	MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year (Simply Wall St.)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-12-23 04:05PM	MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-06-23 09:30AM	The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-27-23 04:05PM	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer (GlobeNewswire)
Mar-18-23 02:06AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 01:33AM	MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021) (Simply Wall St.)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hemrajani Rekha	Director	Jun 25 '25	Sale	2.09	10,684	22,378	39,893	Aug 27 05:12 PM
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Aug 13 '25	Buy	1.29	50,000	64,500	161,811	Aug 13 07:48 PM
Masoud Maher	President and CEO	Aug 13 '25	Buy	1.37	75,000	102,915	175,000	Aug 13 07:47 PM
Erck Stanley C	Director	Aug 13 '25	Buy	1.37	100,000	137,220	398,328	Aug 13 07:47 PM
DOUGLAS RICHARD	Director	Aug 13 '25	Buy	1.39	80,000	111,040	230,577	Aug 13 07:46 PM
Brooke William W	Director	Aug 13 '25	Buy	1.29	50,000	64,500	150,879	Aug 13 07:45 PM
Hemrajani Rekha	Director	Jun 25 '25	Proposed Sale	2.09	10,684	22,378		Jun 25 04:05 PM
Soleymannezhad Ali	Chief Commercial Officer	Mar 18 '25	Sale	3.18	1,211	3,850	59,439	Mar 20 06:49 PM
Sandoval David I.	GENERAL COUNSEL	Mar 18 '25	Sale	3.18	353	1,122	64,219	Mar 20 06:47 PM
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Mar 18 '25	Sale	3.18	6,939	22,061	111,811	Mar 20 06:08 PM
Johnston John Joseph	Director	Jan 27 '25	Option Exercise	2.93	3,000	8,796	144,950	Jan 29 04:13 PM
Johnston John Joseph	Director	Jan 27 '25	Sale	4.64	3,000	13,935	141,950	Jan 29 04:13 PM
Sandoval David I.	GENERAL COUNSEL	Jan 13 '25	Sale	4.54	4,466	20,272	41,447	Jan 14 04:03 PM
Johnston John Joseph	Director	Dec 26 '24	Option Exercise	2.93	3,000	8,796	144,950	Dec 30 04:15 PM
Johnston John Joseph	Director	Dec 26 '24	Sale	4.01	3,000	12,021	141,950	Dec 30 04:15 PM
Johnston John Joseph	Affiliate	Dec 26 '24	Proposed Sale	4.11	12,000	49,320		Dec 26 04:16 PM
Johnston John Joseph	Director	Dec 09 '24	Option Exercise	2.35	2,495	5,863	144,445	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Option Exercise	2.93	505	1,478	142,455	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 09 '24	Sale	3.79	2,495	9,459	141,950	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Sale	3.70	505	1,869	141,950	Dec 10 04:30 PM
Erck Stanley C	Director	Nov 01 '24	Option Exercise	0.04	47,689	1,908	316,807	Nov 05 04:25 PM
Erck Stanley C	Director	Nov 01 '24	Sale	3.72	47,689	177,403	269,118	Nov 05 04:25 PM
Johnston John Joseph	Director	Oct 28 '24	Option Exercise	2.93	3,000	8,778	144,950	Oct 30 04:15 PM
Johnston John Joseph	Director	Oct 28 '24	Sale	3.72	3,000	11,166	141,950	Oct 30 04:15 PM
Erck Stanley C	Director	Oct 01 '24	Option Exercise	0.04	26,082	1,043	295,200	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Option Exercise	0.04	21,607	864	290,725	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 01 '24	Sale	3.78	26,082	98,590	269,118	Oct 02 05:03 PM
Erck Stanley C	Director	Oct 02 '24	Sale	3.71	21,607	80,162	269,118	Oct 02 05:03 PM
Johnston John Joseph	Director	Sep 26 '24	Option Exercise	2.93	3,000	8,778	144,950	Sep 30 04:15 PM
Johnston John Joseph	Director	Sep 26 '24	Sale	3.82	3,000	11,460	141,950	Sep 30 04:15 PM
Johnston John Joseph	Affiliate	Sep 26 '24	Proposed Sale	3.81	9,000	34,290		Sep 26 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MXCT

MaxCyte Inc

Upgrade your FINVIZ experience